Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

Inclusion Criteria: * Major Inclusion Criteria: * Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome * According to the Investigator's opinion will benefit from continuing treatment with relacorilant. Exclusion Criteria: * Major Exclusion Criteria: * Premature discontinuation from a relacorilant parent study * Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism.